International Clinical Trials Day 2026, a year in review: Access to Trials
CLINICAL TRIALS IN REGIONAL, RURAL AND REMOTE AUSTRALIA
With
Amanda Koegelenberg,
CEO, Novatrials
INTERNATIONAL CLINICAL TRIALS DAY SERIES SEGMENT
Filmed in Newcastle, NSW | May 2026
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leading up to 20th May with interviews captured across Australia. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials. The first segment is an example of how in-person clinical trial access has improved for regional, rural and remote communities.
Novatrials is helping transform access to clinical trials for people living in regional, rural and remote communities across the Hunter New England region and beyond. Based in Newcastle, New South Wales, the organisation was founded with a vision to bring innovative medical treatments closer to communities that have traditionally faced significant travel barriers to access state-of-the-art healthcare.
With the first purpose-built Phase 1 clinical trial facility outside of an Australian capital city, Novatrials is expanding opportunities for participants across Newcastle, the wider Hunter region and regional New South Wales to take part in world-class research closer to home. By conducting Phase 1 through to Phase 4 studies across a range of therapeutic areas, the organisation is helping bridge the gap between laboratory innovation and real-world patient care.
According to CEO Amanda Koegelenberg, the investment in the facility illustrates Novatrials’ commitment to ensuring people in regional and remote areas no longer need to travel vast distances to participate in clinical trials, while also bringing more research investment, innovation and healthcare opportunities into the Hunter New England region.
The segment highlights how Novatrials is working collaboratively with partners including the University of Newcastle, Hunter Medical Research Institute and Hunter New England Local Health District to strengthen the region’s research ecosystem and improve access to emerging treatments for local communities.
Source: Adapted from transcript using AI
-
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
-
New reimagined identity LifeSciences Australia repositions for sector
In June 2026, ARCS Australia formally became LifeSciences Australia — a name chosen to reflect the role the organisation plays across Australia’s life sciences sector.
Over more than 40 years, ARCS has grown well beyond its origins as a training and education body for regulatory and clinical specialists. Today, the organisation supports professionals across the entire life sciences sector — from early research through regulation, development and commercialisation — through an expanding range of programs and initiatives.
-
Stronger patient involvement in new medicines
New strategic agreement between Medicines Industry and Government means stronger patient involvement in new medicines.
Medicines Australia has secured a 5-year Strategic Agreement with the Federal Government, centered on earlier patient involvement and influence in the availability of new medicines in Australia.
